Literature DB >> 9337426

Adverse reactions to acetaminophen, ASA, and NSAIDs in children: what alternatives?

M A de Almeida1, A P Gaspar, F S Carvalho, J M Nogueira, J E Pinto.   

Abstract

ASA and NSAIDs are responsible for a large number of adverse reactions. The association of adverse reactions to acetaminophen and to ASA is uncommon, especially in children, and raises the problem of finding alternative treatments. We present a case report of a 7-year-old boy with combined adverse reaction to acetaminophen and ASA/NSAIDs. The child, who had no history of atopy, first displayed the condition at age 6, when he suffered two episodes of urticaria and angioedema, 2 hours after administration of 500 mg of acetaminophen, following two earlier doses of 500 mg (total 1500 mg). At age 7 he suffered a third episode 3 hours after administration of 180 mg of ASA. The patient submitted to oral challenges with acetaminophen (positive at a cumulative dose of 2,040 mg), ASA (positive at a cumulative dose of 204 mg) and nimesulide (negative at a cumulative dose of 119 mg). In conclusion, nimesulide (an NSAID not available in the United States) may be regarded as an alternative treatment in such patients, but more research is needed in pediatric age groups.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337426     DOI: 10.2500/108854197778590560

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  3 in total

1.  National Athletic Trainers' Association position statement: management of asthma in athletes.

Authors:  Michael G Miller; John M Weiler; Robert Baker; James Collins; Gilbert D'Alonzo
Journal:  J Athl Train       Date:  2005 Jul-Sep       Impact factor: 2.860

2.  Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children.

Authors:  Mona Iancovici Kidon; Liew Woei Kang; Chiang Wen Chin; Lim Siok Hoon; Van Bever Hugo
Journal:  Allergy Asthma Clin Immunol       Date:  2007-12-15       Impact factor: 3.406

Review 3.  Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Authors:  C H Wilder-Smith
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.